Physician profile
Harmin Chima
NPI 1538542444
$91,228.14
in general payments reported to CMS, 2019-2025
16 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $10K · 2021: $11K · 2022: $22K · 2023: $15K · 2024: $9,828 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,928 · Consulting Fee: $1,490 · Education: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $15,473.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,790.00 |
| Food and Beverage | $5,928.00 |
| Consulting Fee | $1,490.00 |
| Education | $779.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $85,021.37 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Cvi Contact Lens |
| Alcon Vision LLC | $3,045.58 | 2019-2023 | Systane, Precision 1, Total30 |
| Johnson & Johnson Vision Care, INC. | $1,273.70 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $414.17 | 2019-2021 | |
| Sight Sciences, INC. | $315.64 | 2019-2023 | Tearcare System |
| Visioneering Technologies, INC. | $200.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $171.58 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $160.00 | 2025 | |
| Kala Pharmaceuticals, INC. | $146.03 | 2021-2022 | |
| Abbvie INC. | $134.89 | 2023 | Lumigan, Vuity |
| Bausch & Lomb Americas INC. | $132.31 | 2022 | |
| Oyster Point Pharma, INC. | $93.90 | 2022 | |
| Biotissue Holdings INC. | $46.00 | 2024 | |
| Optos, INC. | $30.29 | 2019 | |
| Integra Lifesciences Corporation | $28.03 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmin Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.